These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 26356511)

  • 21. An early improvement in depressive symptoms predicts symptomatic remission of schizophrenia treated with quetiapine: a multicenter, 4-week case-control study.
    Chou YH; Chiu NM; Yang TT; Feng J; Chan CC; Lee HK;
    Int Clin Psychopharmacol; 2013 Sep; 28(5):255-60. PubMed ID: 23820333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.
    Potkin SG; Weiden PJ; Loebel AD; Warrington LE; Watsky EJ; Siu CO
    Int J Neuropsychopharmacol; 2009 Oct; 12(9):1233-48. PubMed ID: 19419595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES).
    Dubois V; Peuskens J; Geerts P; Detraux J
    Early Interv Psychiatry; 2014 Feb; 8(1):39-49. PubMed ID: 23343330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcome of schizoaffective disorder. Are there any differences with respect to schizophrenia?
    Pinna F; Sanna L; Perra V; Pisu Randaccio R; Diana E; Carpiniello B;
    Riv Psichiatr; 2014; 49(1):41-9. PubMed ID: 24572583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
    Díaz I; Pelayo-Terán JM; Pérez-Iglesias R; Mata I; Tabarés-Seisdedos R; Suárez-Pinilla P; Vázquez-Barquero JL; Crespo-Facorro B
    Psychiatry Res; 2013 Apr; 206(2-3):181-7. PubMed ID: 23159063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia.
    Ho BC; Andreasen NC; Flaum M; Nopoulos P; Miller D
    Am J Psychiatry; 2000 May; 157(5):808-15. PubMed ID: 10784476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.
    Galderisi S; Mucci A; Bitter I; Libiger J; Bucci P; Fleischhacker WW; Kahn RS;
    Eur Neuropsychopharmacol; 2013 Mar; 23(3):196-204. PubMed ID: 22647933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
    Turner MS; Stewart DW
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
    Burton S
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics.
    Wunderink L; Nienhuis FJ; Sytema S; Wiersma D
    Schizophr Bull; 2007 May; 33(3):792-6. PubMed ID: 16894026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insight and recovery in schizophrenic patients.
    Cannavò D; Minutolo G; Battaglia E; Aguglia E
    Int J Psychiatry Clin Pract; 2016; 20(2):83-90. PubMed ID: 26902557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atypical antipsychotic drugs and long-term outcome in schizophrenia.
    Weiden P; Aquila R; Standard J
    J Clin Psychiatry; 1996; 57 Suppl 11():53-60. PubMed ID: 8941171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks.
    Kane JM; Crandall DT; Marcus RN; Eudicone J; Pikalov A; Carson WH; Swyzen W
    Schizophr Res; 2007 Sep; 95(1-3):143-50. PubMed ID: 17644313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychopathological long-term outcome of schizophrenia -- a review.
    Lang FU; Kösters M; Lang S; Becker T; Jäger M
    Acta Psychiatr Scand; 2013 Mar; 127(3):173-82. PubMed ID: 23136879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later.
    Ventura J; Subotnik KL; Gitlin MJ; Gretchen-Doorly D; Ered A; Villa KF; Hellemann GS; Nuechterlein KH
    Schizophr Res; 2015 Feb; 161(2-3):407-13. PubMed ID: 25499044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving patient outcomes in schizophrenia: achieving remission.
    Nasrallah HA; Lasser R
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):57-61. PubMed ID: 17046987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones.
    Iasevoli F; Giordano S; Balletta R; Latte G; Formato MV; Prinzivalli E; De Berardis D; Tomasetti C; de Bartolomeis A
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Feb; 65():34-48. PubMed ID: 26320028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterogeneity of violence in schizophrenia and implications for long-term treatment.
    Volavka J; Citrome L
    Int J Clin Pract; 2008 Aug; 62(8):1237-45. PubMed ID: 18564202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.